



(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
25.10.2000 Bulletin 2000/43

(51) Int. Cl.<sup>7</sup>: **C12Q 1/60**

(21) Application number: **98938983.8**

(86) International application number:  
**PCT/JP98/03771**

(22) Date of filing: **25.08.1998**

(87) International publication number:  
**WO 99/10526 (04.03.1999 Gazette 1999/09)**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

(30) Priority: **27.08.1997 JP 24482197**

(71) Applicant:  
**DAIICHI PURE CHEMICALS CO. LTD.**  
**Chuo-ku Tokyo 103-0027 (JP)**

(72) Inventors:  
• **NAKANISHI, Kazuo-Daiichi Pure Chemicals Co.,  
Ltd.**  
**Ibaraki-ken 301-0852 (JP)**

• **NAKAMURA, Mitsuhiro-Daiichi Pure Chemicals  
Co., Lt**  
**Ibaraki-ken 301-0852 (JP)**  
• **HINO, Koichi-Daiichi Pure Chemicals Co., Ltd.**  
**Ibaraki-ken 301-0852 (JP)**  
• **MANABE, Mitsuhiisa-Daiichi Pure Chemicals  
Co., Ltd.**  
**Ibaraki-ken 301-0852 (JP)**

(74) Representative:  
**Lees, Kate Jane et al**  
**Roystons,**  
**Tower Building,**  
**Water Street**  
**Liverpool L3 1BA (GB)**

(54) **METHODS FOR QUANTITATING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL**

(57) A method for quantitating HDL cholesterol, comprising adding to serum a surfactant selected from among polyethylene alkylene phenyl ethers and polyoxyethylene alkylene tribenzylphenyl ethers and an enzyme reagent for assaying cholesterol, optionally together with a substance capable of inhibiting the reaction of cholesterol in serum lipoproteins with the above enzyme reagent, and determining the amount of the cholesterol thus reacted within a period of time where cholesterol in HDL, among lipoproteins, preferentially reacts with the above enzyme reagent.

By using this method, cholesterol in HDL can be conveniently and efficiently quantitated without resort to any pretreatment such as centrifugation. Thus, it is applicable to various automatic analyzers.

**Description****Technical Field**

5. [0001] This invention relates to a method which with a small sample quantity, permits efficient quantitation of cholesterol in high-density lipoprotein (HDL) only separately from cholesterol in lipoproteins other than HDL by simple procedures without needing procedures such as centrifugation.

**Background Art**

10

[0002] Lipids such as cholesterol are complexed with apoproteins in serum to form lipoproteins. Depending on differences in physical properties, lipoproteins are classified into chylomicron, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and so on. Among these lipoproteins, LDL is known to be one of causative substances which induce arteriosclerosis, while HDL is known to show anti-arteriosclerotic activity.

- 15 [0003] Epidemiologically, the level of cholesterol in HDL is known to show an inverse correlation with the frequency of onset of arteriosclerotic disease. These days, measurements of cholesterol in HDL are widely conducted for the prevention or diagnosis of ischemic heart diseases. As methods known for the measurement of cholesterol in HDL, there are, for example, a method in which HDL is separated from other lipoproteins by ultracentrifugal separation and is then subjected to a cholesterol measurement; and another method in which subsequent to separation of HDL from other  
20 lipoproteins by electrophoresis, its lipid is stained, and the intensity of a developed color is measured. These methods, however, have not been used routinely, because they involve one or more problems in that procedures are intricate and many samples cannot be handled.

- [0004] A method for the measurement of cholesterol in HDL, which is generally and widely used at present in the field of clinical tests, is the precipitation method in which a precipitation reagent is added to a sample to agglutinate lipoproteins other than HDL, the resulting agglutinate is removed by centrifugation, and cholesterol in supernatant which  
25 contains only HDL so isolated is then measured. This method is simpler compared with ultracentrifugation or electrophoresis, but due to the inclusion of the procedures to add the precipitation reagent and to perform the separation, requires each sample in a relatively large quantity, involves a potential problem of producing an analytical error, and does not make it possible to fully automate the entire analysis steps.

- 30 [0005] On the other hand, methods have been studied for the enzymatic fractional quantitation of cholesterol in HDL. Known methods include, for example, to conduct an enzymatic reaction in the presence of a bile salt and a non-ionic surfactant (JP 63-126498 A). This method makes use of the fact that an enzymatic reaction proceeds in proportion to an LDL concentration in an initial stage of the reaction and then in proportion to the concentration of cholesterol in HDL. A problem however exists in accuracy because the reaction with the cholesterol in HDL and the reaction with cholesterol in other lipoproteins cannot be fully distinguished.

- [0006] Also included in the known methods is to have lipoproteins other than HDL agglutinated in advance, to cause cholesterol in HDL alone to react enzymatically, and to inactivate the enzyme and at the same time, to redissolve the agglutinate, followed by the measurement of an absorbance (JP 6-242110 A). This method, however, requires at least three procedures to add reagents so that it can be applied only to particular automatic analyzers, leading to a  
40 problem in wide applicability. Further, this method is not satisfactory from the standpoint of damages to analytical equipments and disposal of the reagents because of the use of a salt at a high concentration upon redissolution of an agglutinate.

- [0007] Furthermore, Japanese Patent No. 2,600,065 discloses a method which makes combined use of a precipitation reagent, which is used in general precipitation methods and causes precipitation of lipoproteins other than HDL, and an ordinary cholesterol measuring reagent to measure the unprecipitated cholesterol in HDL. It is however impossible to measure cholesterol in HDL no matter whichever Example in this patent is followed. Therefore, this patent is considered to be such a patent as failing to include an essential element of its invention by error, and cannot serve as prior art.

50 **Disclosure of the Invention**

- [0008] Concerning the measurement of cholesterol in serum lipoproteins, the present inventors have proceeded with an investigation in various ways. In the course of the investigation, it was found that, when a reaction is conducted between serum and a cholesterol-quantitating enzyme reagent in the presence of a specific surfactant capable of dissolving lipoproteins, only HDL cholesterol reacts first, cholesterol in VLDL reacts next after the reaction of HDL, and with a substantial delay, cholesterol in LDL reacts finally.

- 55 [0009] As a result of further research, it has also been found that the HDL cholesterol alone can be measured by selecting a measurement point as desired such that the first reaction which relies upon the concentration of the HDL

cholesterol can be measured, that the reaction relying upon the concentration of the HDL cholesterol alone can be maintained over an extended time by making a substance, which inhibits the reaction between the cholesterol in serum lipoproteins and the cholesterol-quantitating reagent, exist in the system, and that these methods can also be applied to automatic analyzers, leading to the completion of the present invention.

**[0010]** The present invention therefore provides a method for the quantitation of cholesterol in high-density lipoprotein, which comprises adding a surfactant, which is selected from polyoxyethylene alkylene phenyl ethers and polyoxyethylene alkylene tribenzylphenyl ethers, and a cholesterol-quantitating enzyme reagent to serum; and then measuring a reacted quantity of the cholesterol in the high-density lipoprotein in a time in which the cholesterol in the high-density lipoprotein preferentially reacts with the cholesterol-quantitating enzyme reagent.

**[0011]** The present invention also provides a method for the quantitation of HDL cholesterol as described above, wherein a substance having effect to inhibit a reaction between cholesterol in the serum lipoproteins and the cholesterol-quantitating enzyme reagent is added further.

**[0012]** The present invention also provides a quantitation enzyme and a reagent kit, which make it possible to advantageously practice each of the above-described methods.

## Brief Description of the Drawings

**[0013]**

FIG. 1 is a diagram showing a correlation between analysis data obtained by the method of the present invention and those obtained by the precipitation method in Example 1; and

FIG. 2 is a diagram illustrating a correlation between analysis data obtained by the method of the present invention and those obtained by the precipitation method in Example 2.

## Best Modes for Carrying Out the Invention

**[0014]** The surfactant (hereinafter called the "lipoprotein dissolving agent") for use in the method of the present invention, which is selected from polyoxyethylene alkylene phenyl ethers and polyoxyethylene alkylene tribenzylphenyl ethers, is a surfactant having effect to dissolve lipoproteins. These surfactants can include "Emulgen A-60" (product of Kao Corporation) as a commercially-available example of the former and "Emulgen B66" (product of Kao Corporation) as a commercially-available example of the latter.

**[0015]** These surfactants can be used either singly or in combination. The amount of the surfactant to be used varies depending on the kind of the surfactant, and no particular limitation is imposed thereon. It can be empirically determined for each analyzer, to which the reagent is applied, such that the sensitivity of the analyzer is set to permit detection of HDL cholesterol within a desired measurement time. In general, it is preferred to use the surfactant at a concentration of from 0.01 to 5 wt. %.

**[0016]** The quantitation method according to the present invention may preferably be conducted in the presence of a substance (hereinafter called the "reaction inhibitor") having effect to inhibit the reaction between cholesterol in serum lipoproteins and the cholesterol-quantitating enzyme reagent. Compared with a case where no reaction inhibitor exists, the presence of the reaction inhibitor makes it possible to retain for a longer time a reaction which relies only upon the concentration of HDL cholesterol.

**[0017]** Illustrative of the reaction inhibitor for use in the present invention are substances which exhibit binding affinity to lipoproteins and also surfactants which do not dissolve lipoproteins. They can be used either singly or in combination.

**[0018]** Examples of the substances (hereinafter called the "binding substances") which exhibit binding affinity to lipoproteins can include combinations of polyanions and substances capable of forming divalent metal salts. They can also be such substances as being complexed with HDL to form precipitates. Specific examples of the polyanions can include dextran sulfate, phosphotungstic acid and heparin, while examples of the substances capable of forming divalent metal salts can include the chlorides of divalent metals, such as  $MgCl_2$ ,  $CaCl_2$ ,  $MnCl_2$  and  $NiCl_2$ , and their hydrates. These binding substances can be used either singly or in combination. The amount of the binding substance to be used varies depending its type, and no particular limitation is imposed thereon. It is, however, desired to use them in ranges such that as final concentrations in the reaction, the polyanion amounts to 0.002 to 10 wt. % and the substance capable of forming a divalent metal salt amounts to 0.01 to 5 wt. %, respectively.

**[0019]** Further, the surfactant (hereinafter called the "lipoprotein non-dissolving agent") which does not dissolve lipoproteins can be, for example, a surfactant selected from polyoxyethylene alkyl ethers, polyoxyethylene alkylphenyl ether, polyoxyethylene-polyoxypropylene condensate, polyoxyethylene alkyl ether sulfates, and alkylbenzenesulfonate salts.

**[0020]** Among these, preferred are polyoxyethylene cetyl ether [as a commercial product, "Emulgen 220" (product

of Kao Corporation)] as a polyoxyethylene alkyl ether; polyoxyethylene nonylphenyl ether [as a commercial product, "Emulgen 913" (product of Kao Corporation)] as a polyoxyethylene alkylphenyl ether; "Pluronic F-88" (product of Asahi Denka K.K.) as a polyoxyethylene-polyoxypropylene condensate; polyoxyethylene lauryl ether sulfate sodium salt [as a commercial product, "EMAL 20C" (product of Kao Corporation)]; and sodium dodecylbenzenesulfonate as an alkylbenzenesulfonate.

[0021] These lipoprotein non-dissolving agents can be used either singly or in combination. No particular limitation is imposed on its amount to be used, but it is desired to use it in such a range that, when mixed with a sample, its concentration amounts to 0.01 to 5 wt.%, especially 0.05 to 1 wt.%.

[0022] Upon addition of the lipoprotein dissolving agent and the cholesterol-quantitating enzyme reagent (hereinafter called the "cholesterol reagent") to serum as a sample, they may be added separately or they may be added concurrently as a mixture. On the other hand, the reaction inhibitor can be used by adding it to one of the lipoprotein dissolving agent and the cholesterol reagent or to a mixture thereof. When plural reaction inhibitors are used, they can be mixed together and can be used in a similar manner as in the case of the use of the single reaction inhibitor. As an alternative, they can be added separately to the lipoprotein dissolving agent and the cholesterol reagent, respectively.

[0023] Examples of the cholesterol reagent useful for the quantitation of cholesterol in the present invention can include known cholesterol reagents such as a combination of cholesterol esterase and cholesterol oxidase and a combination of cholesterol esterase and cholesterol dehydrogenase. Of these, the combination of cholesterol esterase and cholesterol oxidase is preferred.

[0024] No particular limitation is imposed on a method which is used to finally measure the reacted quantity of cholesterol subsequent to the addition of these cholesterol reagents. Illustrative are absorbance spectroscopy which is performed by further combining a peroxidase with a chromogen, and a method in which a coenzyme or hydrogen peroxide is directly detected.

[0025] In the method of the present invention, it is necessary to detect the reaction between HDL cholesterol and the cholesterol-quantitating enzyme reagent in the time in which HDL cholesterol preferentially reacts with the cholesterol-quantitating enzyme reagent. Illustrative methods usable for the above detection can include a method in which a reaction which proceeds subsequent to the mixing of the lipoprotein dissolving agent, the cholesterol reagent and the sample is dynamically monitored; and a method (two-point method) in which the reaction of HDL cholesterol is measured by the reaction end-point method and the result of the measurement is corrected by a blank value. When there is a need to monitor the reaction of HDL for an extended time, the reaction which relies upon the concentration of HDL cholesterol alone can be prolonged by adding a reaction inhibitor and hence delaying the cholesterol detection reaction.

[0026] The followings are examples of a reagent or reagent kit usable for the advantageous practice of the method of the present invention:

(1) Reagents or reagent kits including the following two ingredients (a) and (b):

- (a) Lipoprotein dissolving agent, and
- (b) Cholesterol reagent.

(2) The following ingredients (a) to (c):

- (a) Lipoprotein dissolving agent,
- (b) Reaction inhibitor (binding substance, lipoprotein non-dissolving agent), and
- (c) Cholesterol reagent.

[0027] These reagents or reagent kits can be combined with the above-described lipoprotein dissolving agents, cholesterol reagents (cholesterol esterase, cholesterol oxidase, cholesterol esterase, cholesterol dehydrogenase, etc.), reaction inhibitors (binding substances, lipoprotein non-dissolving agents), peroxidase, chromogens, coenzymes, appropriate pH buffers, antioxidants, carriers, and/or the like. Illustrative forms of such reagents or reagent kits can include, in addition to liquid forms, those obtained by lyophilizing such liquid forms.

#### Examples

[0028] This invention will next be described further by Examples. It should however be borne in mind that the present invention is by no means limited to or by the Examples.

#### Example 1

[0029] With respect to each of 50 serum samples containing lipoproteins, the cholesterol in HDL was quantitated

by the method of the present invention and the conventional precipitation method, and the measurement values were compared.

**[0030]** According to the method of the present invention, 100 mM MES buffer (First Reagent; pH 6.5) (300  $\mu$ L) was added to each serum sample (3  $\mu$ L), and about 5 minutes later, a cholesterol quantitation reagent (Second Reagent) (100  $\mu$ L) - which was composed of 1% "Emulgen B-66", 1 U/mL cholesterol esterase, 1 U/mL cholesterol oxidase, 5 U/mL peroxidase, and 100 mM MES buffer (pH 6.5) containing 0.04% disulfobutylmetatoluidine and 0.004% 4-aminoantipyrine - was added. Shortly before Second Reagent and five minutes after its addition, the absorbance was measured at 600 nm (subsidiary wave-length: 700 nm). From a difference in absorbance, the concentration of HDL cholesterol in the serum sample was determined (2-point method). As a calibration substance, a control serum sample with a known concentration was used. The above procedures were conducted using an automatic analyzer "Hitachi Model 7150".

**[0031]** To quantitate the cholesterol in HDL by the precipitation method, on the other hand, an aqueous solution (200  $\mu$ L) which contained 0.3% of dextran sulfate and 2% magnesium chloride was mixed with the sample (200  $\mu$ L), followed by centrifugation at 3,000 rpm for 10 minutes. The supernatant (50  $\mu$ L) was collected, followed by the mixing with a cholesterol quantitation reagent (3 mL) composed of 1% Triton X-100, 1 U/mL cholesterol esterase, 1 U/mL cholesterol oxidase, 5 U/mL peroxidase, and 100 mM MES buffer (pH 6.5) containing 0.04% disulfobutylmetatoluidine and 0.004% 4-aminoantipyrine. After the resulting mixture was incubated at 37°C for 10 minutes, its absorbance at 600 nm was measured to determine the concentration of the cholesterol in HDL.

**[0032]** A correlation diagram of the results obtained by the invention method and the precipitation method are shown in FIG. 1. The invention method, despite its simple procedures, showed an extremely good correlation with the conventional precipitation method.

#### Example 2

**[0033]** With respect to each of 50 serum samples, the cholesterol in HDL was quantitated using the same reagents and the same procedures as in Example 1 except that 1% "Emulgen A-60" was added instead of "Emulgen B-66" in Second Reagent.

**[0034]** Described specifically, First Reagent (300  $\mu$ L) was added to the sample (3  $\mu$ L), and about five minutes later, Second Reagent (100  $\mu$ L) was added. Variations in absorbance at 546 nm (subsidiary wavelength: 660 nm) from the 12th second to the 24th second subsequent to the addition of Second Reagent were measured, and the concentration of HDL cholesterol in the serum sample was determined. As calibration substances, two control serum samples with known concentrations (low concentration and high concentration) were used. The above procedures were conducted using the automatic analyzer "Hitachi Model 7150".

**[0035]** With respect to the same sample, the cholesterol in HDL was quantitated by the same precipitation method in a similar manner as in Example 1. Those measurement values were compared. The results are shown in FIG. 2.

**[0036]** From the results of FIG. 2, the invention method, despite its simple procedures, showed a good correlation with the conventional precipitation method.

#### Example 3

**[0037]** Using the same Second Reagent as that employed in Example 2 and the below-described First Reagent, the cholesterol in HDL in each of 50 serum samples, which contained lipoproteins, was quantitated by the invention method and the conventional quantitation method, and the measurement values were compared. Incidentally, First Reagent A (same as that in Example 2) was added as a control.

[First Reagent]

**[0038]**

First Reagent A:

100 mM MES buffer (pH 6.5).

First Reagent B:

0.2% aqueous solution of "Pluronic F-88" (product of Asahi Denka K.K.).

First Reagent C:

An aqueous solution containing 0.2% sodium phosphotungstate and 100 mM magnesium chloride (pH 6.4).

#### First Reagent D:

- 5 An aqueous solution containing 0.2% "Pluronic F-88", 0.2% sodium phosphotungstate and 100 mM magnesium chloride (pH 6.4).

[0039] To confirm effects of the addition of the reaction inhibitors, the absorbance was measured using different measurement times, that is, from the 12th second to the 24th second, from the 12th second to the 168th second, and from the 12th second to the 312th second, all after the addition of Second Reagent, by using "Hitachi Model 7150".

10 [0040] On the other hand, measurements of HDL by the precipitation method were conducted in a similar manner as in Example 1, and an investigation was made for a correlation with the invention method under the same conditions. Correlation coefficients are shown in Table 1.

15 Table 1

	Measurement time		
	12-24 seconds	12-168 seconds	12-312 seconds
20 First Reagent A	0.922	0.488	0.336
First Reagent B	0.739	0.900	0.846
First Reagent C	0.543	0.946	0.747
25 First Reagent D	0.045	0.972	0.988

[0041] As is appreciated from the results, the First Reagent which did not contain any reaction inhibitor showed good results only in the measurement of the absorbance in the initial stage of the reaction. On the other hand, according to the results of the measurements in which the reagents containing one or more reaction inhibitors, i.e., the 0.2% aqueous solution of "Pluronic F-88" (product of Asahi Denka K.K.), the aqueous solution containing 0.2% sodium phosphotungstate and 100 mM magnesium chloride (pH 6.4) and the aqueous solution containing 0.2% "Pluronic F-88", 0.2% sodium phosphotungstate and 100 mM magnesium chloride (pH 6.4) were used as First Reagents, respectively, all the results showed good correlations (the closer to 1, the higher the correlation) in the measurements over the extended times. It has therefore been confirmed that a reaction inhibitor is effective for prolonging a reaction which relies upon the quantity of HDL cholesterol.

#### Industrial Applicability

[0042] According to the present invention, the cholesterol in HDL can be efficiently quantitated by simple procedures without needing pretreatment such as centrifugal separation. As a specific measurement is feasible with a sample in a small quantity by simple procedures, the present invention can be applied to various automatic analyzers and are extremely useful in the field of clinical tests.

#### Claims

- 45 1. A method for the quantitation of cholesterol in high-density lipoprotein, which comprises adding a surfactant, which is selected from polyoxyethylene alkylene phenyl ethers and polyoxyethylene alkylene tribenzylphenyl ethers, and a cholesterol-quantitating enzyme reagent to serum; and then measuring a reacted quantity of said cholesterol in said high-density lipoprotein in a time in which said cholesterol in said high-density lipoprotein preferentially reacts with said cholesterol-quantitating enzyme reagent.
- 50 2. A method for the quantitation of cholesterol in high-density lipoprotein, which comprises adding a surfactant selected from polyoxyethylene alkylene phenyl ethers and polyoxyethylene alkylene tribenzylphenyl ethers, a substance having effect to inhibit a reaction between cholesterol in serum lipoproteins and a cholesterol-quantitating enzyme reagent, and said cholesterol-quantitating enzyme reagent to serum; and then measuring a reacted quantity of said cholesterol in said high-density lipoprotein in a time in which said cholesterol in said high-density lipoprotein preferentially reacts with said cholesterol-quantitating enzyme reagent.
- 55

3. A method according to claim 2, wherein said substance having effect to inhibit said reaction between cholesterol in serum lipoproteins and said cholesterol-quantitating enzyme reagent is a combination of a surfactant, which does not dissolve lipoproteins, or a polyanion and a substance capable of forming divalent metal ions.
- 5 4. A reagent or reagent kit for the quantitation of cholesterol in high-density lipoprotein, comprising the following ingredients (a) and (b):
  - (a) a surfactant selected from polyoxyethylene alkylene phenyl ethers and polyoxyethylene alkylene tribenzyl-phenyl ethers; and
  - 10 (b) a cholesterol-quantitating enzyme reagent.
5. A reagent or reagent kit for the quantitation of cholesterol in high-density lipoprotein, comprising the following ingredients (a), (b) and (c):
  - 15 (a) a surfactant selected from polyoxyethylene alkylene phenyl ethers and polyoxyethylene alkylene tribenzyl-phenyl ethers;
  - (b) a substance having effect to inhibit a reaction between cholesterol in serum lipoproteins and a cholesterol-quantitating enzyme reagent; and
  - 20 (c) said cholesterol-quantitating enzyme reagent.
- 25
- 30
- 35
- 40
- 45
- 50
- 55

FIG. 1







FIG. 2



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/03771

**A. CLASSIFICATION OF SUBJECT MATTER**  
Int.Cl.<sup>8</sup> C12Q1/60

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
Int.Cl.<sup>8</sup> C12Q1/60

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	JP, 9-313200, A (Daiichi Pure Chemicals Co., Ltd.), 9 December, 1997 (09. 12. 97) & WO, 97/45553, A & AU, 9723075, A	1-5
A	JP, 9-299, A (International Reagents Corp.), 7 January, 1997 (07. 01. 97) & WO, 97/00971, A	1-5
A	JP, 7-301636, A (Kyowa Medex Co., Ltd.), 14 November, 1995 (14. 11. 95) & WO, 95/24647, A & EP, 698791, A & US, 5736406, A	1-5
A	JP, 63-126498, A (Boehringer Mannheim GmbH.), 30 May, 1988 (30. 05. 88) & EP, 265933, A & US, 4892815, A	1-5

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

\* Special categories of cited documents:  
 "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
 "&" document member of the same patent family

Date of the actual completion of the international search  
30 September, 1998 (30. 09. 98)Date of mailing of the international search report  
13 October, 1998 (13. 10. 98)Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)